A Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

February 28, 2025

Study Completion Date

March 31, 2025

Conditions

Novel COVID-19-Infected Pneumonia

Interventions

DRUG

Jaktinib hydrochloride tablets

2 doses per day, 100mg Jaktinib

DRUG

placebo

2 doses per day, placebo

Trial Locations (1)

Changsha Taihe Hospital, Changsha

All Listed Sponsors

lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY

NCT05688839 - A Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia | Biotech Hunter | Biotech Hunter